期刊文献+

晚期非小细胞肺癌靶向治疗进展后的临床研究 被引量:7

下载PDF
导出
摘要 目的探究晚期非小细胞肺癌靶向治疗的后续治疗方法,以提高患者生存时间.方法39例靶向治疗进展后的晚期非小细胞肺癌患者,根据其后续治疗方法将其分为化疗组、姑息组(13例)及原靶向组(11例),化疗组采用培美曲塞或紫衫醇或吉西他滨进行化疗、原靶向组采用原方案继续治疗、姑息组采用姑息治疗方案,统计探究患者靶向治疗进展部位,并比较三组患者预后情况.结果靶向治疗进展部位中,以肺部最高,占41.03%,其次为中枢神经系统及骨,分别占33.33%及23.08%,且多部位转移患者为12例,占30.77%;三组患者治疗后肿瘤进展时间比较,差异均无统计学意义(P>0.05),化疗组患者平均生存时间显著优于原靶向组及姑息组,差异有统计学意义(P<0.05).结论对晚期非小细胞肺癌患者进行靶向治疗后,患者以肿瘤进展部位以肺部为主,且在此时对患者进行化疗,能够有效延长其生存时间.
作者 荣秀梅
出处 《中国实用医药》 2019年第28期74-75,共2页 China Practical Medicine
  • 相关文献

参考文献6

二级参考文献53

  • 1Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer[J]. J Natl Compr Canc Netw, 2010, 8(7): 740-801.
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CACancer J Clin, 2011, 61(2): 69-90.
  • 3Giaccone G, Gallegos RM, Le CT, et al. Erlotinib for frontlinetreatment of advanced non-small cell lung cancer: a phaseⅡ study[J]. Clin Cancer Res, 2006, 12(20 Pt 1): 6049-6055.
  • 4Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy asfirst-line treatment for patients with advanced EGFR mutationpositivenon-small cell lung cancer (OPTIMAL, CTONG-0802):amulticentre, open-label, randomised, phase 3 study[J]. Lancet Oncol,2011, 12(8): 735-742.
  • 5Shigematsu H, Lin L, Takahashi T, et al. Clinical and biologicalfeatures associated with epidermal growth factor receptor genemutations in lung cancers[J]. J Natl Cancer Inst, 2005, 97(5): 339-346.
  • 6Normanno N, de Luca A, Bianco C, et al. Epidermal growth factorreceptor(EGFR) signaling in cancer[J]. Gene, 2006, 366(1): 2-16.
  • 7Rodenhuis S, Slebos RJ. Clinical significance of ras oncogeneactivation in human lung cancer[J]. Cancer Res, 1992, 52(9 Suppl):2665s-2669s.
  • 8Sasaki H, Endo K, Yukiue H, et al. Mutation of epidermal growthfactor receptor gene in adenosquamous carcinoma of the lung[J].Lung Cancer, 2007, 55(1): 129-130.
  • 9Horn L, Pao W. EML4-ALK: honing in on a new target in non-smallcelllung cancer[J]. J Clin Oncol, 2009, 27(26): 4232-4235.
  • 10Bartlett CH, Mino-Kenudson M. Crizotinib for the treatment ofALK-rearranged non. small cell lung cancer: a success story to usherin the second decadeof molecular targeted therapy illneology[J].Oncologist, 2012, 17(11): 1351-1375.

共引文献69

同被引文献58

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部